Why Hims & Hers Stock Just Got Destroyed

Hims & Hers announced a compounded semaglutide (Wegovy/Ozempic lookalike) pill priced at $49/month, prompting an FDA warning and a patent-infringement lawsuit from Novo Nordisk that led to a 25% intraday collapse in HIMS shares. After agreeing to halt sales following the FDA’s action, Hims faces Novo’s demand to enforce the '343 patent' on semaglutide and a request for a permanent ban on compounded versions, a legal outcome that could eliminate Hims’ nascent GLP-1 business and materially affect its growth prospects.

Analysis

Market structure: Novo (NVO) is the clear near-term beneficiary — the FDA/Novo enforcement preserves semaglutide pricing power and likely prevents rapid commoditization Hims (HIMS) attempted. Expect HIMS revenue runway for GLP‑1s to be cut to near zero absent a settlement, keeping branded prices intact (headline spread ~$100–150/mo). Reduced compounding supply tightens effective market supply versus very strong demand, supporting branded margin expansion over 6–18 months and lifting NVO implied forward cashflows.

Risk assessment: Tail risks include a broad injunction against compounding (high impact, ~20–80% downside to HIMS GLP‑1 upside) or a surprise settlement that licenses limited compounded supply (reduces NVO upside). Immediate window (days) is dominated by liquidity and vol; litigation arc will play out over 3–24 months with key rulings in the first 30–90 days. Hidden dependency: HIMS is exposed to supplier/FDA access — seizure or ingredient blacklists would instantly destroy any GLP‑1 product economics.

Trade implications: Direct trade — establish a tactical short in HIMS (size 0.5–2% portfolio) or buy 60–90d put spreads (20–30% OTM) to capture elevated vol; offset with a 1–2% long in NVO via 3–6 month call spreads (5–10% OTM) to play protected pricing. Pair trade — long NVO / short HIMS to isolate GLP‑1 adjudication risk. Rotate 2–5% from telehealth/compounding names into large‑cap pharma and defensive healthcare; rebalance after court milestones (prelim injunction/settlement) within 30–90 days.

Contrarian angles: Consensus may over‑penalize HIMS if GLP‑1s were a small portion of FY27 revenue estimates — check HIMS management guidance and analyst models for >5% revenue sensitivity. Historical parallels (biosimilar injunctions) show litigation sometimes leads to licensing deals that preserve some downstream economics; a settlement could reprice HIMS by 30–70% recovery. Key monitors: court injunction status within 30 days and any FDA enforcement guidance within 14–45 days — these will be primary reversal catalysts.

Key Decisions for Investors

• Establish a tactical short position in HIMS equal to 0.5–2.0% of portfolio (or buy 60–90d put spreads 20–30% OTM) within 1–5 trading days; set take‑profit at 40% and stop‑loss if HIMS rallies >15% from current level.
• Initiate a 1–2% long in NVO via a 3–6 month call spread (5–10% OTM) to capture preserved pricing/margin; target 20–35% upside within 6–12 months and trim on strong post‑ruling rallies.
• Execute a pair trade: long NVO (1%) / short HIMS (1%) to isolate legal/regulatory outcome; close or rebalance positions after key milestones (FDA enforcement memo within 14–45 days, preliminary injunction ruling within 30–90 days).
• Reduce combined exposure to compounding/telehealth equities by 2–5% and rotate into large‑cap pharma/defensive healthcare ETFs over next 2–6 weeks to hedge regulatory/legal risk concentration.
• Monitor three triggers before adding risk: (1) docket entry for preliminary injunction within 30 days, (2) FDA public guidance on compounded GLP‑1 distribution within 14–45 days, (3) any settlement announcement — be prepared to reverse up to 50% of short position upon favorable settlement terms.